Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/06/2024 am IST			5-day change	1st Jan Change
15.46 ^USD	-3.38%		-6.87%	-6.63%

12/06	Transcript : Agenus Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM
16/05	Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	CI

Agenus Inc. Announces Resignation of Jennifer Buell as President and Chief Operating Officer

January 07, 2022 at 03:59 am IST

Agenus Inc. announced that effective December 31, 2021, Dr. Jennifer Buell resigned as Agenus Inc.'s President and Chief Operating Officer to become the President and Chief Executive Officer of MiNK Therapeutics Inc., a subsidiary of the Company.

Latest news about Agenus Inc.

Transcript : Agenus Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM	12/06
Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	16/05	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07/05	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05	MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024	07/05
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	07/05	MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	07/05	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	13/04	MT
Sector Update: Health Care	13/04	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	12/04	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	12/04	CI
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	06/04	MT
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	18/03	MT
Transcript : Agenus Inc., Q4 2023 Earnings Call, Mar 14, 2024	14/03
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	14/03	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	06/03	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	15/02	MT
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	12/02	CI
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	20/12	CI
Agenus Inc.(NasdaqCM:AGEN) dropped from S&P Biotechnology Select Industry Index	18/12	CI
Agenus to Get $25 Million Milestone Payment From Bristol Myers Squibb Under AGEN1777 Licensing Deal	11/12	MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	09/11	MT

Chart Agenus Inc.

Duration

Period

More charts

Company Profile

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agenus Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.46 USD

Average target price

44.25 USD

Spread / Average Target

+186.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AGENUS INC.	-6.63%	325M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research